Curing HIV: Pharmacologic approaches to target HIV-1 latency.
about
Highly significant antiviral activity of HIV-1 LTR-specific tre-recombinase in humanized miceEmerging strategies to deplete the HIV reservoirPredicting the outcomes of treatment to eradicate the latent reservoir for HIV-1Proteasome inhibitors act as bifunctional antagonists of human immunodeficiency virus type 1 latency and replication.Naturally occurring compounds elicit HIV-1 replication in chronically infected promonocytic cells.Mechanisms of HIV Transcriptional Regulation by Drugs of Abuse.Interaction between endogenous bacterial flora and latent HIV infection.Proviral HIV-genome-wide and pol-gene specific zinc finger nucleases: usability for targeted HIV gene therapy.Inhibition of LSD1 reduces herpesvirus infection, shedding, and recurrence by promoting epigenetic suppression of viral genomesDynamic modulation of HSV chromatin drives initiation of infection and provides targets for epigenetic therapies.Generation of HIV latency in humanized BLT mice.Interplay between HIV-1 and Host Genetic Variation: A Snapshot into Its Impact on AIDS and Therapy Response.Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.Temporal transcriptional response to latency reversing agents identifies specific factors regulating HIV-1 viral transcriptional switchHuman immunodeficiency virus (HIV) latency: the major hurdle in HIV eradicationDevelopment of 5' LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individualsThe effects of cocaine on HIV transcriptionHigh levels of CD2 expression identify HIV-1 latently infected resting memory CD4+ T cells in virally suppressed subjects.Deployment of the human immunodeficiency virus type 1 protein arsenal: combating the host to enhance viral transcription and providing targets for therapeutic developmentCan humanized mice reflect the complex pathobiology of HIV-associated neurocognitive disorders?Regulation of CDK9 activity by phosphorylation and dephosphorylation.A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapyCombined approaches for HIV cure.New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo.HIV/AIDS: 30 years of progress and future challenges.Control of HIV latency by epigenetic and non-epigenetic mechanisms.Facts and fiction: cellular models for high throughput screening for HIV-1 reactivating drugs.Eliminating the HIV reservoir.Reactivation of latent HIV by histone deacetylase inhibitors.Inhibitors of the Histone Methyltransferases EZH2/1 Induce a Potent Antiviral State and Suppress Infection by Diverse Viral Pathogens.Latent HIV in primary T lymphocytes is unresponsive to histone deacetylase inhibitors.HIV-1 Eradication: Early Trials (and Tribulations).A Novel Histone Deacetylase Inhibitor, AR-42, Reactivates HIV-1 from Chronically and Latently Infected CD4+ T-cells.Reactivation of latent HIV-1 by inhibition of BRD4.A doubly fluorescent HIV-1 reporter shows that the majority of integrated HIV-1 is latent shortly after infection.CD38+CD8+ and CD38+CD4+ T Cells and IFN Gamma (+874) Polymorphism Are Associated with a Poor Virological Outcome.Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation.A Novel Bromodomain Inhibitor Reverses HIV-1 Latency through Specific Binding with BRD4 to Promote Tat and P-TEFb Association.CTGC motifs within the HIV core promoter specify Tat-responsive pre-initiation complexes.How Might We Cure HIV?
P2860
Q21090483-5C6F58FA-D343-44AA-ADFA-835337DCB548Q27023877-BF54FECB-41EB-4934-A705-6191F31EA461Q28655602-20738B79-F520-41F2-8AC4-F5A2A8FD1487Q33589167-9003156B-B0E1-46F9-8F08-089F807A1FE3Q33678299-8C8AF23B-D17C-44F9-B6F2-EBE328B8A4E3Q33815611-5CA6D6D8-A112-44A0-B7EB-62B7D994DC58Q34686713-3C1FCC3A-1112-4922-A59F-199ABA090674Q35154903-C25E136D-AB9C-4CEC-B54E-DCA6AF707E92Q35559725-A8CE9DB3-B80D-4610-86B9-2D7EF0A35802Q35582225-E61F5186-1C39-4EDB-AD00-55444749F592Q35666126-5B16E29A-3DFB-4D0C-858C-D19B2AC2E3DAQ35993707-C1CA5B3A-8553-4A9C-A19E-1CA6D52514E7Q36076018-9F7E88E1-E21F-481B-BF62-E03A6650FB77Q36125264-31EA7597-9F60-4F26-89BB-261038D5E895Q36330062-19BC5B91-48EB-4988-B0F4-408A7449C876Q36596027-0EEC0670-50FE-4FD9-A30A-7540BACE19D1Q36906001-0B3E4AF1-55E8-4546-945E-7D1A345C10A8Q37123276-442DD3D2-2098-434B-AB65-C40B9B120DC1Q37127522-D4BB0CC1-6105-4049-A63D-2B90ECE72068Q37195155-F6F6FB15-3A83-407B-A5CB-1BE08D7D1847Q37553804-AAF1E6E5-5E9A-4A37-B131-A1A8B5EFD08FQ37604524-C380D148-AC0E-4F8C-8960-A5B2C55C2B12Q37664312-76592FB7-6845-4048-ADD4-ED7B8D7AF8C2Q37695001-1F2FCA4D-766A-4F81-8F57-8D8489972124Q37962420-3C7295BD-5BB4-46FA-B608-C7DFA30B89FBQ37972643-C1D5762E-D314-4E8D-982B-857CD63C5DFCQ37972644-364DAC92-6AA7-47E2-B9D9-4A5750CF662BQ37993454-0CD37018-9159-4F5F-B8A0-C85601C0EDACQ38091753-927A6794-76A8-4353-89EC-10829A05CEC2Q38156730-11E2BB32-A174-4D4A-B44C-C78BBF5BCEDEQ38336315-2DE4F105-8DFD-47DF-8048-54374CE23CF1Q38675631-B4917734-E910-4FE0-AD93-783E064BAD26Q38795594-259B3829-7CCE-4D00-994D-8C3C486F99EBQ39264882-FD67FFBA-F203-4F9F-A13C-943CACF88F8CQ39794074-5D6900B0-FBDF-46D5-B74C-CC0AF2E1677BQ39833706-3997B2A3-16D1-41AB-81C9-926FCD0C50FBQ40091545-5D2D920F-FAB9-4C6F-8BD0-CDE034A030BFQ40150438-D2308C7D-2224-4219-8F4F-93B80BDD2F3EQ41935503-9ED36A7B-7EB0-45DB-ABC4-69A299856462Q42227337-CCD02618-03E0-4675-A19F-DA9180E62858
P2860
Curing HIV: Pharmacologic approaches to target HIV-1 latency.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Curing HIV: Pharmacologic approaches to target HIV-1 latency.
@en
Curing HIV: Pharmacologic approaches to target HIV-1 latency.
@nl
type
label
Curing HIV: Pharmacologic approaches to target HIV-1 latency.
@en
Curing HIV: Pharmacologic approaches to target HIV-1 latency.
@nl
prefLabel
Curing HIV: Pharmacologic approaches to target HIV-1 latency.
@en
Curing HIV: Pharmacologic approaches to target HIV-1 latency.
@nl
P2860
P1476
Curing HIV: Pharmacologic approaches to target HIV-1 latency.
@en
P2093
Shailesh K Choudhary
P2860
P304
P356
10.1146/ANNUREV-PHARMTOX-010510-100237
P577
2011-01-01T00:00:00Z